Iovance Biotherapeutics (IOVA) Competitors $2.34 +0.11 (+4.71%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IOVA vs. APLS, NAMS, TWST, DNLI, KNSA, AGIO, VCEL, RXRX, CGON, and BEAMShould you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include Apellis Pharmaceuticals (APLS), NewAmsterdam Pharma (NAMS), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), Agios Pharmaceuticals (AGIO), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), CG Oncology (CGON), and Beam Therapeutics (BEAM). These companies are all part of the "pharmaceutical products" industry. Iovance Biotherapeutics vs. Its Competitors Apellis Pharmaceuticals NewAmsterdam Pharma Twist Bioscience Denali Therapeutics Kiniksa Pharmaceuticals International Agios Pharmaceuticals Vericel Recursion Pharmaceuticals CG Oncology Beam Therapeutics Iovance Biotherapeutics (NASDAQ:IOVA) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability. Do analysts recommend IOVA or APLS? Iovance Biotherapeutics presently has a consensus price target of $12.22, indicating a potential upside of 418.99%. Apellis Pharmaceuticals has a consensus price target of $39.84, indicating a potential upside of 97.05%. Given Iovance Biotherapeutics' higher possible upside, research analysts clearly believe Iovance Biotherapeutics is more favorable than Apellis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iovance Biotherapeutics 1 Sell rating(s) 6 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.33Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.62 Which has more volatility & risk, IOVA or APLS? Iovance Biotherapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Do insiders & institutionals believe in IOVA or APLS? 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 10.3% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor IOVA or APLS? In the previous week, Iovance Biotherapeutics had 24 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 39 mentions for Iovance Biotherapeutics and 15 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.74 beat Iovance Biotherapeutics' score of 0.26 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 4 Very Positive mention(s) 3 Positive mention(s) 28 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Apellis Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is IOVA or APLS more profitable? Apellis Pharmaceuticals has a net margin of -28.83% compared to Iovance Biotherapeutics' net margin of -176.49%. Iovance Biotherapeutics' return on equity of -49.71% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Iovance Biotherapeutics-176.49% -49.71% -39.18% Apellis Pharmaceuticals -28.83%-99.19%-25.35% Which has preferable valuation & earnings, IOVA or APLS? Apellis Pharmaceuticals has higher revenue and earnings than Iovance Biotherapeutics. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIovance Biotherapeutics$164.07M4.79-$372.18M-$1.24-1.90Apellis Pharmaceuticals$781.37M3.25-$197.88M-$1.79-11.30 SummaryApellis Pharmaceuticals beats Iovance Biotherapeutics on 9 of the 17 factors compared between the two stocks. Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOVA vs. The Competition Export to ExcelMetricIovance BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$786.41M$2.93B$5.50B$9.40BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-1.9020.2928.1319.86Price / Sales4.79259.75424.9198.68Price / CashN/A42.3835.5357.53Price / Book1.017.808.235.71Net Income-$372.18M-$55.11M$3.24B$257.80M7 Day Performance22.02%2.34%0.66%1.12%1 Month Performance16.58%13.02%8.07%11.30%1 Year Performance-73.66%1.46%28.44%16.88% Iovance Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOVAIovance Biotherapeutics4.6212 of 5 stars$2.36+5.6%$12.22+419.0%-76.3%$786.41M$164.07M-1.90500Analyst DowngradeHigh Trading VolumeAPLSApellis Pharmaceuticals4.3172 of 5 stars$17.41-4.7%$39.79+128.5%-52.0%$2.19B$781.37M-9.73770Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionNAMSNewAmsterdam Pharma3.4935 of 5 stars$19.48-1.9%$42.89+120.2%+8.4%$2.19B$45.56M-10.364News CoverageAnalyst ForecastTWSTTwist Bioscience4.2717 of 5 stars$35.54-6.9%$50.40+41.8%-37.5%$2.13B$312.97M-10.94990DNLIDenali Therapeutics4.6841 of 5 stars$14.27-2.9%$33.71+136.3%-37.9%$2.07B$330.53M-5.34430Positive NewsKNSAKiniksa Pharmaceuticals International3.3578 of 5 stars$28.12+0.9%$38.80+38.0%+27.2%$2.05B$481.17M-112.48220Upcoming EarningsInsider TradeAGIOAgios Pharmaceuticals4.4094 of 5 stars$35.27-2.2%$58.60+66.1%-16.8%$2.04B$36.50M3.14390Analyst RevisionVCELVericel3.782 of 5 stars$39.65-5.0%$61.14+54.2%-28.9%$2.00B$237.22M1,322.11300News CoveragePositive NewsRXRXRecursion Pharmaceuticals1.1407 of 5 stars$4.91-6.8%$7.00+42.6%-37.3%$2.00B$58.84M-2.77400High Trading VolumeCGONCG Oncology2.5105 of 5 stars$26.18-2.7%$58.67+124.1%-30.7%$2.00B$662K-17.3461News CoverageAnalyst ForecastBEAMBeam Therapeutics2.2432 of 5 stars$19.18-4.1%$48.75+154.2%-26.5%$1.93B$63.52M-4.16510 Related Companies and Tools Related Companies Apellis Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Twist Bioscience Competitors Denali Therapeutics Competitors Kiniksa Pharmaceuticals International Competitors Agios Pharmaceuticals Competitors Vericel Competitors Recursion Pharmaceuticals Competitors CG Oncology Competitors Beam Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IOVA) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
